The recommended starting dose of injectable Semaglutide is typically 0.25 mg once weekly, with the option to increase to 0.5 mg and eventually 1 mg based on individual patient response and tolerability
Question 2: are clinical trial results peer-reviewed
As the demand for medical weight loss continues to rise, many people are turning to innovative treatment options that go beyond traditional diet and exercise
Retatrutide is an investigational weekly injection targeting three hormone receptors (GLP1, GIP and glucagon) to support weight loss
Do not use if you are pregnant, nursing, taking any prescription or over-the-countermedications or supplements, or if you have or suspect you may have a medical condition,including but not limited to: high or low blood pressure, cardiac arrhythmia, stroke, heart,liver or kidney disease, seizure disorder, thyroid disease, psychiatric disease, diabetes,prostate enlargement or if you are taking a MAO Inhibitor